Ascelia Pharma AB (SE0010573113) — research page
SE · se-cm-kg/XSTO/SE0010573113 · as of 2026-11-06
Identity and listing
Ascelia Pharma AB is listed on Nasdaq Stockholm under the ticker SE0010573113, with ISIN SE0010573113 and LEI 5493002YR9VCJJPWYN08. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Ascelia Pharma AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0010573113 | source · 2026-11-06 |
| ISIN | SE0010573113 | source · 2026-11-06 |
| LEI | 5493002YR9VCJJPWYN08 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 25 filings across 25 filing days in the twelve months to 2026-11-06. The median gap between filing days is 12.0 days. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3), 1 day before the record date. The Nasdaq Stockholm median is 9.5 days for cadence, 30.0 filings and 7.0 days of latency across 398 issuers. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 25 | 12 | 1 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | Quarterly Report Q3 2026: Orviglance® update following FDA Type A meeting |
| 2026-10-11 | Investor News | Investor News | Ascelia Pharma provides Orviglance® update following FDA Type A meeting |
| 2026-09-24 | Investor News | Investor News | Ascelia Pharma announces publication of Orviglance clinical study in Journal of Magnetic Resonance Imaging |
| 2026-09-10 | Investor News | Investor News | Ascelia Pharma completes FDA Type A meeting on Orviglance NDA |
| 2026-08-20 | Half Year financial report | Half Year financial report | Focus on the Path Forward for Orviglance |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record and its location are not on the record. Auditor changes are not on the record, because this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, because this register has no lifecycle type map yet. The record shows the issuer as listed, not halted.
Orderability
The outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter's orderability section carries no client categories. The chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
Three research houses are named on the issuer's investor-relations page: DNB Carnegie, Redeye and ABG Sundal Collier.
| research house | analyst | source · read date |
|---|---|---|
| DNB Carnegie | Maria Karlsson Osipova | issuer page · 2026-11-12 |
| Redeye | Fredrik Thor | issuer page · 2026-11-12 |
| ABG Sundal Collier | Georg Tigalonov-Bjerke | issuer page · 2026-11-12 |
Open research
Four openly published research notes are on the record: DNB Carnegie on 2025-05-19, ABG Sundal Collier on 2025-04-25, DNB Carnegie on 2025-02-11, and Edison Group on 2019-05-21.
| date | publisher | note | kind |
|---|---|---|---|
| 2025-05-19 | DNB Carnegie | Ascelia Pharma | issuer-sponsored |
| 2025-04-25 | ABG Sundal Collier | Improving cancer contrast | issuer-sponsored |
| 2025-02-11 | DNB Carnegie | Ascelia Pharma | issuer-sponsored |
| 2019-05-21 | Edison Group | Ascelia Pharma | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No years are sealed for the issuer. The earliest sealed date of the market is not on the record, and the live record began on no date.
Sources
11 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0010573113 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.ascelia.com/equity-research/ (coverage)
- 10.7
- https://www.ascelia.com/wp-content/uploads/2025/05/250519-Carnegie-Access.pdf (open research)
- 10.8
- https://www.ascelia.com/wp-content/uploads/2025/05/Improving-cancer-contrast.pdf (open research)
- 10.9
- https://www.ascelia.com/wp-content/uploads/2025/02/250211-Carnegie-Access.pdf (open research)
- 10.10
- https://www.ascelia.com/wp-content/uploads/2019/05/190521-Equity-Research-Edison-Group.pdf (open research)
- 10.11
- https://mcp.se-cm-kg.ai/record/XSTO/SE0010573113 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0010573113"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:b093093b8a16052a.